AbbVie — Pharmaceutical Intelligence | Humanexa Signals

CompetitiveJune 26, 2026

AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders

A new clinical trial is evaluating upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab.

Recent signals(32)

FDA Accepts Supplement for Lupron by AbbVie

Study on Guselkumab Therapy's Impact on NAFLD in PsA Patients

FDA Accepts Supplement Application for HADLIMA by Samsung Bioepis

Upcoming catalysts(1)

AbbVie — Emraclidine

Regulatory activity(15)

FDA Accepts Supplement for Lupron by AbbVie

FDA Accepts Supplement Application for HADLIMA by Samsung Bioepis

FDA Approves Supplemental Application for KALETRA by AbbVie

Clinical activity(13)

Study on Guselkumab Therapy's Impact on NAFLD in PsA Patients

Epcoritamab Trial in Japanese R/R B-Cell NHL Shows Safety and Efficacy Potential

Janssen's Guselkumab Compared to Risankizumab in Crohn's Disease Study Initiated

Competitive activity(4)

B2227 vs. Vraylar: Pharmacokinetics Study in Schizophrenia Launched

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

AbbVie Evaluates AGN-151586 with BOTOX for Glabellar Lines in New Trial

Assets

Therapeutic areas

Indications

Get signals before the market moves

FDA Approves Supplemental Application for KALETRA by AbbVie

FDA Accepts Supplemental Application for Norvir (Ritonavir) by AbbVie

B2227 vs. Vraylar: Pharmacokinetics Study in Schizophrenia Launched

FDA Accepts Supplement for RINVOQ (Upadacitinib) by AbbVie

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)

FDA Accepts Supplemental NDA for Linzess by AbbVie

Epcoritamab Trial in Japanese R/R B-Cell NHL Shows Safety and Efficacy Potential

FDA Accepts Supplemental NDA for VENCLEXTA by AbbVie

FDA Accepts Supplemental Application for Lupron by AbbVie

FDA Accepts Supplement Application for HADLIMA (Adalimumab Biosimilar)

FDA Approves Supplemental Application for RINVOQ LQ by AbbVie

Janssen's Guselkumab Compared to Risankizumab in Crohn's Disease Study Initiated

APT Comparison Study to Evaluate Atogepant vs. Topiramate and Propranolol for Migraine Prevention

FDA Accepts Supplement for SKYRIZI (Risankizumab) by AbbVie

AbbVie Initiates Study on Surabgene Lomparvovec for Neovascular AMD

AbbVie Evaluates AGN-151586 with BOTOX for Glabellar Lines in New Trial

AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy

AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders

Phase 1 Study of ABBV-722 Shows Focus on Safety and Pharmacokinetics

AbbVie initiates pediatric study of Risankizumab for Ulcerative Colitis

AbbVie initiates trial for ubrogepant in menstrual migraine treatment

AbbVie initiates trial for telisotuzumab adizutecan in mCRC with FOLFOX and bevacizumab/panitumumab

AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes

AbbVie Evaluates XEN63 Gel Stent for Glaucoma via Two Surgical Approaches

FDA Accepts Supplement Application for SKYRIZI (Risankizumab)

FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

FDA Accepts Supplemental Application for Norvir (Ritonavir) by AbbVie

FDA Accepts Supplement for RINVOQ (Upadacitinib) by AbbVie

FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)

FDA Accepts Supplemental NDA for Linzess by AbbVie

FDA Accepts Supplemental NDA for VENCLEXTA by AbbVie

FDA Accepts Supplemental Application for Lupron by AbbVie

FDA Accepts Supplement Application for HADLIMA (Adalimumab Biosimilar)

FDA Approves Supplemental Application for RINVOQ LQ by AbbVie

FDA Accepts Supplement for SKYRIZI (Risankizumab) by AbbVie

FDA Accepts Supplement Application for SKYRIZI (Risankizumab)

FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

APT Comparison Study to Evaluate Atogepant vs. Topiramate and Propranolol for Migraine Prevention

AbbVie Initiates Study on Surabgene Lomparvovec for Neovascular AMD

AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy

Phase 1 Study of ABBV-722 Shows Focus on Safety and Pharmacokinetics

AbbVie initiates pediatric study of Risankizumab for Ulcerative Colitis

AbbVie initiates trial for ubrogepant in menstrual migraine treatment

AbbVie initiates trial for telisotuzumab adizutecan in mCRC with FOLFOX and bevacizumab/panitumumab

AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes

AbbVie Evaluates XEN63 Gel Stent for Glaucoma via Two Surgical Approaches

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders